Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin or placebo plus lenalidomide and rituximab for relapsed or refractory diffuse large B-cell lymphoma
2020-002686-33Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Brentuximab vedotin + lenalidomide + rituximab with Placebo + lenalidomide + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: active.
02
Drugs
brentuximab vedotinlenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-002686-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002686-33.